Proprietary antibodies
Unlocking new opportunities in biologic innovation
Over the years, Diatheva has developed advanced R&D capabilities, expanding its expertise to build a proprietary pipeline of monoclonal antibodies.
These assets are the result of internal research activities and are now available for strategic partnerships and clinical development.
Our programs focus on innovative targets in oncology and infectious diseases, addressing areas of high unmet medical need.
Our proprietary monoclonal antibodies
A portfolio of proprietary monoclonal antibodies in late preclinical development, ready to advance through partnership.
Anti-CEACAM1 - DIA-12.3
Next-generation immune checkpoint inhibitor for solid tumors
DIA-12.3 targets CEACAM1, an emerging immune checkpoint involved in tumor angiogenesis and immune suppression.
By restoring NK and T cell-mediated cytotoxicity, it enables a strong antitumor immune response.
Anti-CD99 - DIA 3.2-3
Targeting hematological malignancies and sarcomas
A fully human monoclonal antibody targeting CD99, associated with AML, ALL, and Ewing’s sarcoma.
It combines direct tumor cell killing with modulation of the tumor microenvironment, while selectively sparing healthy cells.
Anti-1,3-β-glucans - DIA-T51
Innovative approach to drug-resistant fungal infections
A humanized IgG1 monoclonal antibody targeting 1,3-β-glucans, designed to address invasive fungal infections such as Candida and Aspergillus.
Developed to tackle antimicrobial resistance, it offers a novel therapeutic strategy in infectious diseases.
Get in Touch Now!
